Drug Target Ontology
Names
More detailed information about this field from each metasource.
Drug Target Ontology
metasource: Fairsharing.org
version: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
metasource: Biontology / Bioportal
version: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
DTO
metasource: Fairsharing.org
version: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
metasource: Biontology / Bioportal
version: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
Names
More detailed information about this field from each metasource.
Drug Target Ontology
metasource: Fairsharing.orgversion: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
metasource: Biontology / Bioportal
version: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
DTO
metasource: Fairsharing.orgversion: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
metasource: Biontology / Bioportal
version: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
Names
More detailed information about this field from each metasource.
Drug Target Ontology
metasource: Fairsharing.orgversion: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
metasource: Biontology / Bioportal
version: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
DTO
metasource: Fairsharing.orgversion: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
metasource: Biontology / Bioportal
version: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
Drug Target Ontology (DTO) is developed as a reference for drug targets with the longer-term goal to create a community standard that will facilitate the integration of diverse drug discovery information from numerous heterogeneous resources. The first version of the DTO consists of asserted class hierarchies of the four IDG protein families, GPCRs, kinases, ion channels, and nuclear hormone receptors. Protein classes are linked to tissue and disease via different levels of confidence. DTO also contains drug target development classifications, a large collection of cell lines from the LINCS project and relevant cell-disease and cell-tissue relations. DTO is modeled in OWL2-DL to enable further classification by inference reasoning and SPARQL queries. DTO is implemented following a modularization approach. DTO will serve as the organizational framework for drug targets in the IDG PHAROS User Interface Portal (https://pharos.nih.gov).
Description
More detailed information about this field from each metasource.
Drug Target Ontology (DTO) is developed as a reference for drug targets with the longer-term goal to create a community standard that will facilitate the integration of diverse drug discovery information from numerous heterogeneous resources. The first version of the DTO consists of asserted class hierarchies of the four IDG protein families, GPCRs, kinases, ion channels, and nuclear hormone receptors. Protein classes are linked to tissue and disease via different levels of confidence. DTO also contains drug target development classifications, a large collection of cell lines from the LINCS project and relevant cell-disease and cell-tissue relations. DTO is modeled in OWL2-DL to enable further classification by inference reasoning and SPARQL queries. DTO is implemented following a modularization approach. DTO will serve as the organizational framework for drug targets in the IDG PHAROS User Interface Portal (https://pharos.nih.gov).
metasource: Fairsharing.orgversion: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
Drug Target Ontology (DTO) is being developed at the University of Miami in the research group of Stephan Schürer. DTO is supported by grant U54CA189205 (Illuminating the Druggable Genome Knowledge Management Center, Tudor Oprea, PI) awarded by the NCI through the NIH Common Fund. It is a component of the Illuminating the Druggable Genome (IDG) project (https://commonfund.nih.gov/idg). The DTO project develops a novel semantic framework to formalize knowledge about drug targets with a focus on the current IDG protein families. The DTO is developed as a reference for drug targets with the longer-term goal to create a community standard that will facilitate the integration of diverse drug discovery information from numerous heterogeneous resources. The first version of the DTO consists of asserted class hierarchies of the four IDG protein families, GPCRs, kinases, ion channels, and nuclear hormone receptors. Protein classes are linked to tissue and disease via different levels of confidence. DTO also contains drug target development level classifications developed in the IDG project (http://targetcentral.ws/), and functional and qualitative annotations and classifications for kinase proteins, GPCR ligands and ion channels. DTO is modeled in OWL2-DL to enable further classification by inference reasoning and SPARQL queries. DTO is implemented following a modularization approach. DTO is used as the organizational framework for drug targets in the IDG PHAROS User Interface Portal (https://pharos.nih.gov) and also the Tin-X Target Importance and Novelty Explorer (http://newdrugtargets.org).
metasource: Biontology / Bioportalversion: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
Webpage:
http://drugtargetontology.org/Webpage
More detailed information about this field from each metasource.
http://drugtargetontology.org/
metasource: Fairsharing.orgversion: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
metasource: Biontology / Bioportal
version: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
Licence:
Name: Creative Commons Attribution 3.0 Unported (CC BY 3.0)Licence name
More detailed information about this field from each metasource.
Creative Commons Attribution 3.0 Unported (CC BY 3.0)
metasource: Fairsharing.orgversion: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
This ontology is licensed under Creative Commons Attribution-ShareAlike 4.0 International.
metasource: Biontology / Bioportalversion: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
Licence URL
More detailed information about this field from each metasource.
https://creativecommons.org/licenses/by/3.0/
metasource: Fairsharing.orgversion: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
https://creativecommons.org/licenses/by-sa/4.0/
metasource: Biontology / Bioportalversion: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
Publications:
Publications
More detailed information about this field from each metasource.
Drug target ontology to classify and integrate drug discovery data
PMID: 29122012
metasource: Fairsharing.org
version: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
http://drugtargetontology.org/
metasource: Biontology / Bioportal
version: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
Publications
More detailed information about this field from each metasource.
Drug target ontology to classify and integrate drug discovery data
PMID: 29122012
metasource: Fairsharing.org
version: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
http://drugtargetontology.org/
metasource: Biontology / Bioportalversion: 1.1.1 extracted_at: 2022-11-04T11:10:15.597147, http://bioportal.bioontology.org/ontologies/DTO
-
Drug target ontology to classify and integrate drug discovery data
PubMed citations: 16.
16 articles citing: Drug target ontology to classify and integrate drug discovery data
Knowledge Graphs for Indication Expansion: An Explainable Target-Disease Prediction Method. PMID:35360842
Systematic illumination of druggable genes in cancer genomes. PMID:35196490
Targeting the ion channel TRPM7 promotes the thymic development of regulatory T cells by promoting IL-2 signaling. PMID:33293462
The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer. PMID:33205077
Building a Pharmacogenomics Knowledge Model Toward Precision Medicine: Case Study in Melanoma. PMID:33084582
Recent progress on cheminformatics approaches to epigenetic drug discovery. PMID:33010481
PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor. PMID:32985588
Ontological approach to the knowledge systematization of a toxic process and toxic course representation framework for early drug risk management. PMID:32883995
Machine and deep learning approaches for cancer drug repurposing. PMID:31904426
How to Illuminate the Druggable Genome Using Pharos. PMID:31898878
LINCS Data Portal 2.0: next generation access point for perturbation-response signatures. PMID:31701147
Exploring the dark genome: implications for precision medicine. PMID:31270560
How to Develop a Drug Target Ontology: KNowledge Acquisition and Representation Methodology (KNARM). PMID:30848456
Network, Transcriptomic and Genomic Features Differentiate Genes Relevant for Drug Response. PMID:30319692
Unexplored therapeutic opportunities in the human genome. PMID:29472638
Ontological representation, integration, and analysis of LINCS cell line cells and their cellular responses. PMID:29322930 - http://drugtargetontology.org/
Tags:
Tags
More detailed information about this field from each metasource.
disease
metasource: Fairsharing.org
version: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
protein
metasource: Fairsharing.org
version: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
Tags
More detailed information about this field from each metasource.
disease
metasource: Fairsharing.orgversion: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
protein
metasource: Fairsharing.orgversion: FAIRsharing.org: DTO; Drug Target Ontology; DOI: https://doi.org/10.25504/FAIRsharing.tke3y2; Last edited: July 13, 2021, 8:52 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
Need help integrating and/or managing biomedical data?